Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2018)
16 slides from Genetic Technologies's shareholder meeting presentation, Nov 29, 2018
Slide 1: 2018 Annual General Meeting ASX Announcement
GENETIC TECHNOLOGIES LIMITED DISEASE RISK ASSESSMENT ON A GLOBAL SCALE 1 ASX ANNOUNCEMENT 29 November 2018 2018 Annual General Meeting Melbourne, Australia; 29 November 2018 : Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”) is pleased to release the attached slide show presentation
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may containforward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933 and Section 21E of the U.S. SecuritiesExchange Act of 1934 with respect to the financialcondition,resultsandbusinessachievements/performanceof Genet
Slide 3: By 2020, 50 percent of global health care expenditures will be spent on chronic diseases
By 2020, 50 percent of global health care expenditures will be spent on these diseases: Cancer Cardiovascular Respiratory Global healthcare spending is expected to reach $8.7 trillion by 2020. The number of diabetes sufferers globally is expected to rise from 415 Chronic disease accounts for 84% mil
Slide 4: Targeted screening reduces the cost of healthcare
Targeted screening reducesthe costof healthcare. Early detection reduces the need for expensive, late-stage care. Limited screening resources can be targeted to those at increased risk. 4
Slide 5: Our flagship test, BREVAGen plus, predicts a woman's risk of developing breast cancer
Our flagshiptest,BREVAGenplus®, predicts a woman’sriskof developing breast cancer. 5
Slide 6: BREVAGen plus allows providers to target limited resources
Screening BREVAGenplus® allows providers to target limited resources to women who are most likely to Medication develop cancer. breast Lifestyle 6
Slide 7: Additional screening tests are in development
Additional screening tests are in development. rb (] G'ti rt-(] rb 0" :b' .s (] G1i ':SJ <:; G'ti c..; 'Z> 0 1) 'Z> 0-r:-0 ?yo 2} 01> <( 1> cz',""' o" () ) r§ <:< " () 7
Slide 8: Respected collaborators accelerate development
Respected collaborators accelerate development. The University of Melbourne is Australia’s peak research university. Our collaboration with Professor John Hopper led to our NHMRC Grant. The National Health and Medical Research Council is Australia's peak funding body for medical research. 8 Ohio Sta
Slide 9: Healthy China 2030
• Comprehensive healthcare plan for 1.5 billion people • Disease prevention to control costs Healthy China 2030 • GTG genetic tests predict an individual’s risk of developing disease. • Healthcare resources directed to people most at risk. • Early intervention treatment. and less costly 9
Slide 10: Hainan Medical Pilot Zone
10 • Part of the Hainan Free Trade Zone Initiative • Allows foreign companies to safely introduce IP and repatriate profits Through our partnership with Zishan Health, GTG has been invited to participate. HainanMedicalPilot Zone
Slide 11: Hainan Medical Pilot Zone
11 • Part of the Hainan Free Trade Zone Initiative • Allows foreign companies to safely introduce IP and repatriate profits Through our partnership with Zishan Health, GTG has been invited to participate. HainanMedicalPilot Zone
Slide 12: Zishan Health: fast-track access to the Chinese FDA
Fast-track access to the Chinese FDA Connections into the Chinese healthcare sector Zishan Health Consultancy Track record of introducing non-Chinese companies into the Hainan Free Trade Zone In-country sales and marketing, both in Hainan and other provinces 12
Slide 13: Advancing genomics on the blockchain
Development of region-specific tests where data will be managed on the blockchain Advancing genomicson the blockchain Combining technology capabilities GTG core with blockchain Continuing to work with Blockchain Global to identify new opportunities 13
Slide 14: 2018: Aligning Structure with Strategy
R&D to develop new tests Refreshed Board eCommerce Platform While these initiatives impacted our ability to generate short-term revenue, we eliminated the cost of an Global Expansion ineffective sales force, focused on R&D and initiated the partnerships that will secure our global future. 2018: Alig
Slide 15: Thank You
Thank You Paul Kasian Chairmanand CEO Email: paul.kasian@gtglabs.com Web: www.gtgcorporate.com 15
Slide 16: Thank You
Thank You 2 Paul Kasian Chairman and CEO Email: paul.kasian@gtglabs.com Web: www.gtgcorporate.com
Genetic Technologies — Shareholder Meeting (November 2018) on 6ix